Pelosi plan to lower drug prices faces political challenges

Amy Baxter | | Health Exec | Policy & Regulations

House Speaker Nancy Pelosi’s (D-CA) bill to lower drug prices is facing new challenges as congressional Democrats debate changes to the plan, The Hill reported.

Centrist Democrats are warning leadership that if the plan moves further to the left, it could start to lose support and votes. Others are pushing for stronger reforms to “toughen up” the legislation.

“Pelosi will have to thread the needle between these dueling factions as she plans to bring the measure to the floor as soon as mid-November,” the report reads.

Pelosi introduced the plan in September, calling the bill The Lower Drug Costs Now Act. The plan enables the HHS to negotiate lower prices for hundreds of Medicare drugs––something currently prohibited under law.

See the full story below:

House Democrats clash over Pelosi's drug pricing bill

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Report: Elon Musk stepping down from DOGE in ‘coming weeks’
Heart Rhythm Society legislative advocacy group raising funds for electrophysiology
HHS ‘dramatic restructuring’ begins as employees turned away by security
California ballot measure named after Luigi Mangione lands on AG’s desk
FDA announces new recall of Medtronic surgical devices over safety concerns
300+ groups urge Senate GOP to reject Medicaid cuts

Around the web

Cardiovascular Business
ACC urges RFK Jr. to make Medicare reform a priority, warns against mass layoffs

The American College of Cardiology has sent a letter to HHS Secretary Robert F. Kennedy Jr. that outlines some of the organization’s central priorities and concerns. 

Radiology Business
FDA announces recall of Medtronic interventional radiology devices after 17 injuries, 4 deaths

One product is being pulled from the market, and the other is receiving updated instructions for use.

AI in Healthcare
What federal regulators can learn from the states about AI oversight

If the Trump administration continues taking a laissez-faire stance toward AI—including AI used in healthcare—why not let the states go it alone on regulating the technology?